Mounjaro Week 1 Weight Loss: What Real Reviews Tell You (and What the Evidence Says)

Why do most week-1 reviews focus on hunger rather than the scales?

Browse accounts from people in their first week on tirzepatide and a pattern emerges quickly: they are surprised by how little they want to eat. The appetite signal seems to quieten. Portions that once felt normal start feeling like too much. That shift often arrives before the scales respond in any meaningful way.

This makes clinical sense. Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, that are involved in regulating appetite and gastric emptying. The result is a slower passage of food through the stomach and a stronger satiety signal after eating. Your body starts receiving different information about when it has had enough. That change can be felt within days. Weight, however, is a lagging indicator, it reflects cumulative energy balance over time, not a single week's appetite shift.

The NHS page on tirzepatide confirms that weight loss with this medicine develops over the course of treatment, not overnight. Expecting a dramatic first-week result sets a benchmark the medicine was never designed to hit at this stage. The first pen's job is to settle your system into the new hormonal environment. Therapeutic weight loss builds from there.

If you want a broader look at the trajectory people describe across the early weeks, the evidence on how long Mounjaro takes to work is worth reading alongside this page.

What do reviews say about side effects in week 1?

Honest week-1 accounts mention side effects alongside the appetite changes, and that honesty is useful. The most commonly reported experiences in the first week are nausea, a feeling of fullness that borders on uncomfortable, burping and, for some people, looser stools or constipation. These are the same effects documented in clinical trials and listed in the medicine's patient information leaflet.

The important context: for most people these effects are mild to moderate, and they tend to ease within a few days to roughly two weeks as the body adapts to the starting dose. They are most noticeable immediately after the first injection. Eating smaller, lower-fat meals and staying hydrated appears, from both clinical advice and patient accounts, to help manage them.

Severe or persistent symptoms are different. Severe stomach pain that extends to the back, signs of an allergic reaction, or significant dehydration from repeated vomiting or diarrhoea all warrant prompt medical attention, contact your GP or call 111, and do not wait for your next scheduled check-in. Suspected side effects can also be reported via the MHRA's Yellow Card scheme.

It is worth reading the accounts in before and after Mounjaro reviews with this in mind: the people who describe difficult early weeks often go on to describe markedly different experiences once the dose settles.

Is no weight loss in week 1 a sign that Mounjaro isn't working?

This is probably the single most common concern people bring to online forums after their first week. The short answer: no, it is not a reliable sign of anything except early treatment.

The SURMOUNT-1 trial (which involved over 2,500 adults with obesity across 72 weeks) reported average weight reduction of around 20–21% at the 15mg maintenance dose. Those results accumulated over the full course of dose escalation. They did not arrive in week one. The titration schedule that starts at 2.5mg exists precisely because the medicine needs to be introduced at a level the body tolerates, not at the level that produces maximum effect.

Comparison weeks are also worth considering. Fluid retention, hormonal variation, different sodium intake, and even the timing of when you weigh yourself can all shift the number on the scales by a kilogram or more without any meaningful change in body fat. Some people find their weight dips slightly in week 1 from reduced food and fluid intake; others see no movement at all. Both are consistent with early treatment on 2.5mg.

If four weeks in you are still uncertain whether the medicine is having any effect, our page on no weight loss at week 4 goes into that question in more depth. For now, one week is simply too short a window to draw conclusions.

What should you actually take from other people's week-1 accounts?

Reviews and personal accounts can be genuinely useful, but they work best when you know what to extract from them. Week-1 experiences on Mounjaro are highly variable. One person notices appetite change within 24 hours; another feels little different until the second or third injection. Neither is wrong. Starting body weight, diet composition, how recently someone ate before injecting, individual gut physiology, all of these influence the early experience.

What consistent reviews do usefully confirm: the appetite shift is real, it can arrive before the scales move, early gastrointestinal symptoms are common but usually temporary, and the first week is not predictive of the overall outcome. The people describing steady, significant loss at months three, six and twelve almost universally describe an unspectacular first four weeks.

For a broader picture of how the medicine's evidence and access work, the Mounjaro treatment overview sets out what is known from the full clinical programme. If cost is a factor in deciding whether to start, the honest guide to Mounjaro pricing in the UK covers what private treatment actually involves. And if you are already in week 2 and wondering what comes next, week 2 without visible progress addresses that question directly.

One note on timing: if you are thinking about starting and want same-day dispatch, orders need to be in by 12pm on a working day, something worth factoring in if you are planning around a Monday start or a bank holiday.

Mounjaro is a prescription-only medicine. A GPhC-registered prescriber reviews each consultation individually before any treatment is issued. If you are ready to have that conversation, you can speak to our prescribers through a free consultation.